Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvation Bio Inc.NUVB · Entity 4384 | CHIEF PEOPLE OFFICER | June 23, 2026 | June 24, 2026 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | EVP Human Resources | March 20, 2019 | March 22, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvation Bio Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 32,591 |
Ending reported balance
After 2026-06-23 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-06-23 · Exercise / conversion · Acquired 90,380 · Balance 122,971 Row 2 · 2026-06-23 · Exercise / conversion · Acquired 34,620 · Balance 157,591 Row 3 · 2026-06-23 · Sale · Disposed 125,000 · Balance 32,591 F1: Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. F2: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.085. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2034-02-27 | Direct | 409,620 |
Reported balance
After 2026-06-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-23 · Exercise / conversion · Disposed 90,380 · Balance 409,620 F3: Option vests as to 25% on the one year anniversary of February 29, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-01-21 | Direct | 220,190 |
Reported balance
After 2026-06-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-23 · Exercise / conversion · Disposed 34,620 · Balance 220,190 F4: Option vests as to 25% on September 30, 2020 and in equal monthly installments thereafter over the following three years, subject to Reporting Person's continuous service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.
F2: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.085. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: Option vests as to 25% on the one year anniversary of February 29, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.
F4: Option vests as to 25% on September 30, 2020 and in equal monthly installments thereafter over the following three years, subject to Reporting Person's continuous service on each such vesting date.
RIGEL PHARMACEUTICALS INC
Report date March 20, 2019 · Filed March 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2028-03-21 | Direct | 62,500 |
Reported balance
After 2019-03-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-20 · Grant · Acquired 62,500 · Balance 62,500 F1: On March 21, 2018, the reporting person was granted a performance based option to purchase 62,500 shares of common stock based on a specific performance metric. On March 20, 2019, it was determined that the performance metric had been met. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 21, 2018, the reporting person was granted a performance based option to purchase 62,500 shares of common stock based on a specific performance metric. On March 20, 2019, it was determined that the performance metric had been met.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 24, 2026 23:09 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 34,620 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001734780-26-000004 · form4-06242026_110645.xml · derivative · entry 5 Markel Stacy · CIK 0001734780 · CHIEF PEOPLE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,190 Underlying: Class A Common Stock · 34,620 shares Expires 2030-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option vests as to 25% on September 30, 2020 and in equal monthly installments thereafter over the following three years, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 23:09 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 90,380 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001734780-26-000004 · form4-06242026_110645.xml · derivative · entry 4 Markel Stacy · CIK 0001734780 · CHIEF PEOPLE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 409,620 Underlying: Class A Common Stock · 90,380 shares Expires 2034-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of February 29, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 23:09 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | SaleClass A Common Stock | 125,000 | $6.03 | $753,187.50 |
DisclosureSEC source: 0001734780-26-000004 · form4-06242026_110645.xml · nonDerivative · entry 3 Markel Stacy · CIK 0001734780 · CHIEF PEOPLE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,591 F1 · kind: Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.085. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 23:09 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 34,620 | $1.74 | $60,238.80 |
DisclosureSEC source: 0001734780-26-000004 · form4-06242026_110645.xml · nonDerivative · entry 2 Markel Stacy · CIK 0001734780 · CHIEF PEOPLE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 23:09 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 90,380 | $1.87 | $169,010.60 |
DisclosureSEC source: 0001734780-26-000004 · form4-06242026_110645.xml · nonDerivative · entry 1 Markel Stacy · CIK 0001734780 · CHIEF PEOPLE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 748,130 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001734780-26-000003 · form4-03042026_120307.xml · derivative · entry 2 Markel Stacy · CIK 0001734780 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 748,130 Underlying: Class A Common Stock · 748,130 shares Expires 2036-02-26 F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| June 18, 2025 Filed Jun 18, 2025 20:05 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 10,000 | $1.71 | $17,100.00 |
DisclosureSEC source: 0001415889-25-017660 · form4-06182025_040613.xml · nonDerivative · entry 1 Markel Stacy · CIK 0001734780 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,591 F1 · balance_after: Includes 3,000 shares acquired on May 19, 2025 under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 23:35 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001415889-25-006699 · form4-03042025_110320.xml · derivative · entry 2 Markel Stacy · CIK 0001734780 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2035-02-27 F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2025, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 22:24 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001415889-24-006310 · form4-03042024_100304.xml · derivative · entry 2 Markel Stacy · CIK 0001734780 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2034-02-27 F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 23:02 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001209191-23-014892 · doc4.xml · derivative · entry 2 Markel Stacy · CIK 0001734780 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2033-02-27 F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 21:17 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001209191-22-048154 · doc4.xml · derivative · entry 1 Markel Stacy · CIK 0001734780 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Class A Common Stock · 450,000 shares Expires 2032-08-28 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:57 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001209191-22-014825 · doc4.xml · derivative · entry 2 Markel Stacy · CIK 0001734780 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2032-02-27 F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:50 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 254,810 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-010344 · doc4.xml · derivative · entry 2 Markel Stacy · CIK 0001734780 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,810 Underlying: Class A Common Stock · 254,810 shares Expires 2030-01-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F5 · price: Received in exchange for an option to purchase 254,810 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest as to 25% on September 30, 2020 and in equal monthly installments thereafter over the following three years. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:50 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 398,935 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010344 · doc4.xml · derivative · entry 1 Markel Stacy · CIK 0001734780 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,935 Underlying: Class A Common Stock · 398,935 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest as to 20% on October 5, 2023, 20% on October 5, 2023 and 60% on October 5, 2025, subject to achievement of performance criteria. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 23:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001179110-19-004211 · edgar.xml · derivative · entry 1 Markel Stacy · CIK 0001734780 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2028-03-21 F1 · derivative.exercise_date: On March 21, 2018, the reporting person was granted a performance based option to purchase 62,500 shares of common stock based on a specific performance metric. On March 20, 2019, it was determined that the performance metric had been met. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 23:41 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 137,500 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001179110-19-000936 · edgar.xml · derivative · entry 1 Markel Stacy · CIK 0001734780 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Stock · 137,500 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019. Read SEC document |
| March 21, 2018 Filed Mar 23, 2018 22:18 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001179110-18-004818 · edgar.xml · derivative · entry 1 Markel Stacy · CIK 0001734780 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-03-21 F1 · derivative.exercise_date: One fourth (1/4th) of the option vests one year from March 19, 2018 and thereafter the balance of the option vests in equal monthly installments over the next thirty-six (36) months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.